How to Stop Prostate Bleeding: Causes and Treatments

Prostate bleeding, which shows up as blood in the urine (hematuria), stems from a handful of treatable causes, and the right approach depends on what is driving it. The most common culprit is benign prostatic hyperplasia, where an overgrowth of tiny blood vessels inside the prostate makes it vulnerable to bleeding. Prostate cancer, radiation therapy, infections, and blood-thinning medications round out the list. Treatments range from medications that shrink those fragile vessels over weeks to minimally invasive procedures that stop active bleeding within hours, so the path forward depends on how urgently the bleeding needs to be controlled and what is causing it in the first place.

Why the Prostate Bleeds

The prostate sits just below the bladder and wraps around the urethra, so when something goes wrong inside it, blood often shows up at the beginning or end of urination. That pattern of initial or terminal hematuria is a strong signal that the bleeding source is in the lower urinary tract rather than the kidneys or ureters.¹ Understanding why the prostate is bleeding matters because the treatment differs sharply depending on the underlying cause.

In benign prostatic hyperplasia (BPH), the gland doesn’t just grow larger; it also sprouts an unusually dense network of tiny blood vessels. Research comparing men with BPH-related hematuria to controls found that the density of small blood vessels beneath the surface lining was more than double in the bleeding group.² Separate work looking at the architecture of BPH tissue showed that blood vessel density in the areas of active nodular growth was significantly higher than in surrounding non-nodular tissue, reaching levels comparable to what is seen in prostate cancer specimens.³ These fragile, densely packed vessels are easy to rupture with even minor mechanical irritation from a catheter, straining during urination, or the stretching that accompanies an enlarged gland.

In prostate cancer, pathological blood vessel growth is even more pronounced. Tumor angiogenesis drives the formation of new capillaries, capillary sprouts, and abnormally permeable vessels. The density of these pathological vessels tends to be higher when the tumor extends beyond the prostate capsule, and imaging can reveal increased blood volume, blood flow, and vessel permeability within the gland.⁴ The practical upshot is that cancer-related prostate bleeding can be harder to control because the abnormal vessels are more widespread and less responsive to the medications used in BPH.

Radiation therapy for prostate cancer creates a different bleeding mechanism. The radiation damages the small blood vessels lining the rectum and bladder neck, leading to telangiectasias, clusters of dilated, fragile capillaries that can bleed intermittently for years. In one long-term follow-up of men treated with moderately hypofractionated radiation, moderate-to-severe telangiectasia was seen in the majority of patients at every annual check, with severe grades peaking around the third year after treatment.⁵ This is important to know because radiation-related bleeding can surface long after treatment ends, catching people off guard.

First Steps When You See Blood

If you notice blood in your urine and have a known prostate condition, the first move is almost always to increase your fluid intake and contact your urologist. Mild hematuria sometimes resolves on its own when the source is a few fragile vessels in an enlarged prostate. But when bleeding is heavy, especially with clots, you may need urgent care.

In the hospital setting, continuous bladder irrigation is the standard first-line intervention for significant prostatic bleeding. A large-bore catheter is placed into the bladder, and sterile saline is flushed through continuously to prevent clots from forming and blocking urine flow. Data from a study tracking irrigation outcomes after transurethral surgery found that the irrigation ran clear about 62% of the total observation time, with traces of blood present roughly 31% of the time and active bleeding visible less than 1% of the time.⁶ Clot retention, where clots block the catheter and prevent drainage, occurred in a small number of patients and sometimes required a return to the operating room for clot evacuation or cauterization of the bleeding point.⁶

The takeaway for patients is that continuous irrigation is effective but labor-intensive. It keeps the bladder from filling with clots and usually brings bleeding under control while the medical team addresses the underlying cause. If you are sent home after an episode of prostatic hematuria, your doctor will likely ask you to drink plenty of water, avoid heavy lifting and straining, and return immediately if clots appear or you cannot urinate.

Medications That Shrink Prostatic Blood Vessels

For BPH-related hematuria, the most effective long-term medical treatment is a class of drugs called 5-alpha reductase inhibitors, specifically finasteride and dutasteride. These drugs work by blocking the conversion of testosterone to dihydrotestosterone inside the prostate, which over time shrinks both the gland and, critically, its abnormal blood vessel network.

The evidence for finasteride is remarkably strong for a urologic bleeding problem. In a study of 28 men with gross hematuria from prostatic bleeding who took finasteride for at least six months, the bleeding stopped entirely in about 90% of them.⁷ That is a high success rate for a pill that works gradually rather than instantly. The mechanism isn’t mysterious: as the prostate shrinks, the dense tangle of fragile vessels thins out, and the bleeding surface diminishes.

Dutasteride works through the same pathway and has shown similar results. A pilot study found that just six weeks of dutasteride reduced blood vessel density in the periurethral area of the prostate, the zone closest to where bleeding is most likely to cause visible hematuria.⁸ A randomized trial comparing pretreatment with finasteride and dutasteride before transurethral resection of the prostate found that both drugs significantly reduced operative blood loss and prostatic microvessel density after about four weeks of use, with no meaningful difference between the two drugs.⁹

The main caveat is timing. These drugs take weeks to months to reach their full effect. If you are dealing with active, heavy bleeding, finasteride alone won’t be enough to stop it acutely. But once the bleeding is controlled with irrigation or another short-term measure, starting a 5-alpha reductase inhibitor is one of the most effective strategies to prevent recurrence. Your doctor may keep you on the medication indefinitely if BPH-related bleeding has been a recurring problem.

Tranexamic Acid During Prostate Surgery

For men undergoing prostate surgery, perioperative bleeding is a major concern, particularly for those already taking blood thinners. Tranexamic acid (TXA), a drug that stabilizes blood clots by blocking a key enzyme that dissolves them, has shown real promise in this setting. A multicenter prospective study of men undergoing endoscopic prostate enucleation found that intraoperative TXA reduced the odds of bleeding complications by about 83% on multivariable analysis. The time needed to achieve hemostasis during surgery was also shortest in the groups receiving TXA.¹⁰

TXA is not typically used as a standalone treatment for chronic prostatic hematuria, but it is increasingly part of the perioperative toolkit. If you are scheduled for prostate surgery and are worried about bleeding, ask your surgical team whether TXA will be used during the procedure. The data suggest a meaningful protective effect, especially for men who cannot safely stop their blood-thinning medications.

Surgical Options When Bleeding Persists

When medications and conservative measures fail to control prostatic bleeding, surgical intervention becomes the next step. The traditional approach, transurethral resection of the prostate (TURP), involves inserting an instrument through the urethra and shaving away the overgrown prostatic tissue, including the bleeding vessels. TURP has been the gold standard for decades, but it carries its own bleeding risk, which has pushed the development of newer techniques.

Holmium laser enucleation of the prostate (HoLEP) has emerged as a strong alternative, particularly for men who are at higher bleeding risk. A matched-pair analysis comparing HoLEP to TURP in patients on various blood-thinning regimens found that HoLEP provided better perioperative hemostatic control and caused fewer bleeding complications in this high-risk population.¹¹ The laser seals blood vessels as it cuts, which is a meaningful advantage when the tissue being removed is riddled with fragile vasculature.

Diode laser vaporization is another option gaining traction, especially for bleeding-prone patients. A randomized trial comparing diode laser vaporization to bipolar transurethral vaporization in men at elevated bleeding risk found that the laser group had significantly less hemoglobin drop after surgery, shorter irrigation time, earlier catheter removal, and shorter hospital stays.¹² For patients concerned about a prolonged recovery or extended hospitalization, these laser-based approaches offer a real practical advantage.

After any transurethral procedure, some degree of post-operative bleeding is expected. The management approaches used to deal with it range from conservative (continued irrigation and catheter traction) to endoscopic (returning to the operating room to cauterize the specific bleeding vessel) to, rarely, open surgical packing of the prostatic fossa.¹³ Most post-surgical bleeding resolves with the conservative approach.

Prostate Artery Embolization for Stubborn Bleeding

When hematuria resists both medication and standard surgery, or when a patient is too frail for a surgical procedure, prostate artery embolization (PAE) offers a minimally invasive alternative. A radiologist threads a thin catheter through an artery in the groin or wrist and navigates it to the small arteries feeding the prostate. Tiny particles are then injected to block blood flow to the bleeding tissue.

In men with advanced prostate cancer who had refractory hematuria, PAE was technically successful in about 89% of cases, and gross hematuria stopped in roughly two-thirds of patients, with no procedure-related complications reported.¹⁴ A broader review of PAE for intractable prostate bleeding noted that minor complications ranged from 10% to 50% across published series, and hematuria recurred in anywhere from 10% to 57% of patients over follow-up periods.¹⁵ That recurrence rate is not ideal, but for patients who have failed other treatments or who cannot tolerate surgery, PAE represents a valuable option that avoids general anesthesia and open surgery.

PAE also has the side benefit of reducing lower urinary tract symptoms and relieving urinary retention in some prostate cancer patients, which means it can address multiple problems at once.¹⁵ If your urologist suggests embolization, it typically means the bleeding has not responded to more conservative approaches, and the procedure is worth discussing with an interventional radiologist.

Intravesical Alum for Last-Resort Bleeding

For truly intractable hematuria, where the prostate (or bladder involvement from prostate cancer) keeps bleeding despite medications, irrigation, and surgical attempts, intravesical alum instillation is a salvage option. Alum, an aluminum-based compound, is dissolved in sterile water and continuously irrigated into the bladder, where it causes surface proteins on the bleeding tissue to coagulate and form a barrier that slows blood loss.

A contemporary evaluation of alum treatment in patients with intractable hemorrhagic cystitis found an overall success rate of 60%, defined as no need for further bleeding therapy before hospital discharge. Among patients who responded, alum also reduced transfusion requirements: about 82% of patients needed transfusions in the 30 days before alum treatment, compared to 59% in the 30 days after.¹⁶ Case reports specifically addressing prostatic carcinoma as the bleeding source have also shown that alum irrigation can resolve hematuria when other conservative measures have failed, with no toxicity observed.¹⁷

Alum is not a first-line therapy. It is uncomfortable, requires continuous catheter-based irrigation, and the patients who reach this point are usually very sick. But it fills an important gap for people who are not candidates for embolization or further surgery, and the fact that it works in more than half of otherwise untreatable cases makes it a meaningful option to keep in the toolkit.

Managing Blood Thinners Around Prostate Bleeding

One of the most common and anxiety-producing questions men face when prostate bleeding develops is what to do about their anticoagulant or antiplatelet medications. Many men with prostate problems are older and take blood thinners for heart conditions, atrial fibrillation, or a history of blood clots. Stopping these drugs reduces bleeding but raises the risk of stroke and cardiovascular events. Continuing them makes bleeding harder to control.

The data here are more nuanced than a simple “hold your blood thinners” instruction. A study of men undergoing TURP found that patients on anticoagulants were at about 1.6 times the risk of acute bleeding and 11 times the risk of prolonged hematuria lasting more than two weeks. Among the specific drugs, rivaroxaban carried a higher acute bleeding risk than apixaban, roughly doubling it.¹⁸ That same study also found that patients on anticoagulants had a significantly elevated stroke risk in the perioperative period, highlighting the tension between bleeding control and thromboembolic safety.

For HoLEP specifically, a retrospective analysis compared patients who held their blood thinners before surgery to those who continued them. Overall, outcomes were similar between the two groups, but there were meaningful differences by drug type. Patients who held clopidogrel had shorter hospital stays and higher rates of same-day catheter removal and discharge. Patients who held warfarin had shorter procedure and morcellation times.¹⁹ The emerging picture is that laser-based procedures may be safe enough to perform even when certain blood thinners are continued, but the decision should be individualized based on the specific medication, the patient’s cardiovascular risk, and the surgical technique being used.

If you are on blood thinners and experiencing prostatic bleeding, do not stop them on your own. The decision to hold, bridge, or continue anticoagulation needs to be made jointly by your urologist and your cardiologist or primary care physician, weighing the seriousness of the bleeding against your personal clotting risk.

Prostate Cancer Drugs and Bleeding Risk

Men receiving treatment for advanced prostate cancer often take hormone-based therapies alongside blood thinners, raising the question of whether certain prostate cancer drugs interact with anticoagulants to increase bleeding. Research specifically examining the concurrent use of abiraterone, a commonly prescribed prostate cancer medication, with direct oral anticoagulants (DOACs) found no increased risk of major or any bleeding episodes compared to non-DOAC users. Major bleeding rates were roughly 5% in the DOAC group versus 4% in the comparison group, with hazard ratios showing no meaningful difference.²⁰

This is reassuring but limited. Drug interactions in cancer treatment are complex, and the absence of a signal with one combination doesn’t guarantee safety across all prostate cancer drugs. If you are on both an anticoagulant and a prostate cancer therapy and develop new or worsening hematuria, bring it up with your oncology team rather than assuming it is just the prostate acting up. The combination could matter in ways that haven’t been fully studied yet.

When Radiation Causes the Problem

Radiation-induced prostatic and periprostatic bleeding occupies its own treatment niche. Unlike BPH-related bleeding, which responds well to 5-alpha reductase inhibitors, radiation damage to the microvasculature creates chronic telangiectasias that can ooze intermittently for years. As noted earlier, severe telangiectasia was found in a substantial portion of patients for at least five years after treatment.⁵

The treatment approach for radiation-related bleeding tends to follow a stepwise pattern. Mild bleeding is often managed conservatively with hydration and monitoring. If bleeding escalates, hyperbaric oxygen therapy is sometimes used to promote healing of the irradiated tissue, though the evidence for this is mixed and availability is limited. Cauterization of visible telangiectasias during cystoscopy can help when specific bleeding points are identifiable. For refractory cases, the salvage options described earlier, including alum instillation and embolization, come into play.

The critical thing to understand about post-radiation bleeding is its unpredictability. You might go months without any visible blood and then have an episode that looks alarming. Each episode does not necessarily mean the underlying problem is getting worse; telangiectasias can bleed and then seal over and then bleed again as their fragile walls are stressed. Keeping your urologist informed about the frequency and severity of episodes helps them decide when to escalate from watchful waiting to active intervention.